HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 136.63% from the company’s previous close. HC Wainwright also issued estimates for Genmab A/S’s Q1 2025 earnings at $0.18 EPS, Q2 2025 earnings at $0.39 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.49 EPS and FY2025 earnings at $1.50 EPS.

Other equities research analysts also recently issued research reports about the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Trading Down 0.8 %

Shares of NASDAQ:GMAB opened at $21.13 on Thursday. The firm’s 50 day moving average is $21.07 and its two-hundred day moving average is $23.96. The firm has a market capitalization of $13.98 billion, a P/E ratio of 20.51, a PEG ratio of 0.57 and a beta of 0.97. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the business earned $0.47 earnings per share. Analysts predict that Genmab A/S will post 1.28 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers lifted its stake in Genmab A/S by 7.1% during the second quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after purchasing an additional 1,236 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after acquiring an additional 145,689 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Genmab A/S during the 2nd quarter worth $457,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Genmab A/S in the 2nd quarter worth $1,354,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.